#Pharma Sanofi wins Japanese approval for diabetes drug Lyxumia - PMLiVE http://t.co/B10Rwx8fsP cc @mtu31
July 01, 2013
Publicité
/http%3A%2F%2Fwww.pmlive.com%2F__data%2Fassets%2Fimage%2F0019%2F450802%2FSanofi_reception.jpg)
Sanofi wins Japanese approval for diabetes drug Lyxumia
Japanese authorities have licensed the use of Sanofi's new treatment for type 2 diabetes Lyxumia (lixisenatide). The drug is a key part of Sanofi's diabetes portfolio and complements its basal insulin brand Lantus (insulin glargine), which brought in €5bn last year to make it the company's biggest selling product.